Physician profile
Benjamin Yan
NPI 1811158587
$1,884.34
in general payments reported to CMS, 2019-2025
23 companies · $69.81 in 2025
The $69.81 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $165 · 2021: $68.63 · 2022: $43.44 · 2023: $106 · 2024: $853 · 2025: $69.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $300 · Travel and Lodging: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $300.39 |
| Travel and Lodging | $203.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $665.25 | 2019-2024 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $320.97 | 2019-2025 | |
| Brainlab, INC. | $232.28 | 2021-2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning, Image Guided Surgical Device |
| Amgen INC. | $153.80 | 2019-2021 | |
| Genzyme Corporation | $64.95 | 2019-2020 | |
| Abbvie INC. | $56.85 | 2019-2020 | |
| Daiichi Sankyo INC. | $48.78 | 2020-2023 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $36.35 | 2020-2021 | |
| Lilly USA, LLC | $30.41 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $30.35 | 2019 | |
| Janssen Biotech, INC. | $26.26 | 2019 | |
| Eisai INC. | $25.69 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $24.17 | 2023 | Pylarify |
| Mylan Institutional INC. | $21.31 | 2023 | Ogivri, Fulphila |
| Sobi, INC | $21.03 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $20.87 | 2019 | |
| Clovis Oncology, INC. | $17.43 | 2019 | |
| Incyte Corporation | $16.79 | 2019 | |
| Boston Scientific Corporation | $16.36 | 2025 | Spaceoar Vue System - 10ml |
| Agios Pharmaceuticals, INC. | $15.17 | 2019 | |
| Puma Biotechnology, INC. | $14.14 | 2022 | |
| Astellas Pharma US INC | $13.31 | 2019 | |
| Emd Serono, INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.